AeroShot Pure Energy names Mechanica as first agency of record
AeroShot Pure Energy, a revolutionary new brand that delivers consumers an on-demand airborne shot of instant energy, has named Mechanica as its first agency of record, according to Ted Nelson, chief executive officer of the independent brand development firm. The account was awarded after a regional review and billings were not disclosed.
The highly anticipated retail launch is expected in Boston and New York City in January 2012.
AeroShot is the first product from Breathable Foods, Inc, an independent spin off of Paris based ArtScience Labs, which launched in 2010 and established an office in Cambridge, MA., in 2011. ArtScience Labs is a network of labs that combine the sciences and arts to create breakthrough products founded by Harvard Professor David Edwards.
Working with AeroShot's CEO, Tom Hadfield, Mechanica will create a full suite of marketing and brand experience programs including, brand strategy, naming, design, packaging, brand ID, creative, website development, sales, retail and trade marketing support in addition to social media, public relations and sampling/experiential/campus ambassador programs.
New work will appear as part of the product launch in 2012 and Mechanica will handle media planning and buying chores as well. Currently, the pre-launch site www.aeroshots.com is live and free sample codes are available for redemption and request.
PCI Synthesis announces successful FDA inspection
PCI Synthesis, Inc. (www.pcisynthesis.com), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, announced the successful completion of its eighth FDA inspection of the company's commercial manufacturing site in Newburyport.
Additionally, PCI received its sixth product pre-approval; with that pre-approval, PCI's partner expects to launch a new drug in 2012. Over the past year, PCI launched five new proprietary APIs in the laboratory for the generic and OTC markets with exclusive supply agreements, exceeding its goal of four per year.